95 related articles for article (PubMed ID: 24813477)
1. The 5-lipoxygenase inhibitor tepoxalin induces oxidative damage and altered PTEN status prior to apoptosis in canine osteosarcoma cell lines.
Loftus JP; Cavatorta D; Bushey JJ; Levine CB; Sevier CS; Wakshlag JJ
Vet Comp Oncol; 2016 Jun; 14(2):e17-30. PubMed ID: 24813477
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of 5-lipoxygenase expression in canine osteosarcoma and the effects of a dual 5-lipoxygenase/cyclooxygenase inhibitor on osteosarcoma cells in vitro and in vivo.
Goupil RC; Bushey JJ; Peters-Kennedy J; Wakshlag JJ
Vet Pathol; 2012 Sep; 49(5):802-10. PubMed ID: 22287649
[TBL] [Abstract][Full Text] [Related]
3. Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft.
Sottnik JL; Hansen RJ; Gustafson DL; Dow SW; Thamm DH
Vet Comp Oncol; 2011 Jun; 9(2):118-30. PubMed ID: 21569197
[TBL] [Abstract][Full Text] [Related]
4. Pro-apoptotic effects of tepoxalin, a cyclooxygenase/lipoxygenase dual inhibitor, on canine synovial fibroblasts.
Sunaga T; Oh N; Hosoya K; Takagi S; Okumura M
J Vet Med Sci; 2012 Jun; 74(6):745-50. PubMed ID: 22240988
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis.
Agnello KA; Reynolds LR; Budsberg SC
Am J Vet Res; 2005 Jun; 66(6):966-72. PubMed ID: 16008217
[TBL] [Abstract][Full Text] [Related]
6. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
[TBL] [Abstract][Full Text] [Related]
7. Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase.
Kazmi SM; Plante RK; Visconti V; Taylor GR; Zhou L; Lau CY
J Cell Biochem; 1995 Feb; 57(2):299-310. PubMed ID: 7759567
[TBL] [Abstract][Full Text] [Related]
8. 5-lipoxygenase expression and tepoxalin-induced cell death in squamous cell carcinomas in cats.
Wakshlag JJ; Peters-Kennedy J; Bushey JJ; Loftus JP
Am J Vet Res; 2011 Oct; 72(10):1369-77. PubMed ID: 21962280
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers.
Waldman SA; Vitow C; Osborne B; Gillen L; Argentieri DC; Wong FA; Smith IL; Chow AT; Misiti J; Bjornsson TD
J Clin Pharmacol; 1996 May; 36(5):462-8. PubMed ID: 8739025
[TBL] [Abstract][Full Text] [Related]
10. Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.
Shoeneman JK; Ehrhart EJ; Charles JB; Thamm DH
Vet Comp Oncol; 2016 Jun; 14(2):e45-57. PubMed ID: 24923332
[TBL] [Abstract][Full Text] [Related]
11. Sodium selenite-induced apoptosis mediated by ROS attack in human osteosarcoma U2OS cells.
Chen XJ; Duan FD; Zhang HH; Xiong Y; Wang J
Biol Trace Elem Res; 2012 Jan; 145(1):1-9. PubMed ID: 21826611
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt.
Liu B; Shi ZL; Feng J; Tao HM
Cell Biol Int; 2008 May; 32(5):494-501. PubMed ID: 18078766
[TBL] [Abstract][Full Text] [Related]
13. Cellular effects of a turmeric root and rosemary leaf extract on canine neoplastic cell lines.
Levine CB; Bayle J; Biourge V; Wakshlag JJ
BMC Vet Res; 2017 Dec; 13(1):388. PubMed ID: 29237458
[TBL] [Abstract][Full Text] [Related]
14. Akt activation by arachidonic acid metabolism occurs via oxidation and inactivation of PTEN tumor suppressor.
Covey TM; Edes K; Fitzpatrick FA
Oncogene; 2007 Aug; 26(39):5784-92. PubMed ID: 17369849
[TBL] [Abstract][Full Text] [Related]
15. Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors.
Matsuyama M; Yoshimura R; Mitsuhashi M; Hase T; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Int J Oncol; 2004 Apr; 24(4):821-7. PubMed ID: 15010818
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray.
Russell DS; Jaworski L; Kisseberth WC
J Vet Diagn Invest; 2018 Jul; 30(4):504-509. PubMed ID: 29629647
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor PTEN is mutated in canine osteosarcoma cell lines and tumors.
Levine RA; Forest T; Smith C
Vet Pathol; 2002 May; 39(3):372-8. PubMed ID: 12014501
[TBL] [Abstract][Full Text] [Related]
18. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor, in man.
Depré M; Van Hecken A; Verbesselt R; Verpooten GA; Arnout J; Brunner F; Jurgens A; Pousset V; Chow A; Baldauf C; Vermylen J; De Broe M; De Schepper PJ
Int J Clin Pharmacol Res; 1996; 16(1):1-8. PubMed ID: 9001924
[TBL] [Abstract][Full Text] [Related]
19. Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells.
Nielsen-Preiss SM; Silva SR; Gillette JM
J Cell Biochem; 2003 Dec; 90(5):964-75. PubMed ID: 14624456
[TBL] [Abstract][Full Text] [Related]
20. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
